167 related articles for article (PubMed ID: 11403179)
21. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
Bodei L; Cremonesi M; Grana C; Rocca P; Bartolomei M; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1038-46. PubMed ID: 15150675
[TBL] [Abstract][Full Text] [Related]
22. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
de Jong M; Bakker WH; Krenning EP; Breeman WA; van der Pluijm ME; Bernard BF; Visser TJ; Jermann E; Béhé M; Powell P; Mäcke HR
Eur J Nucl Med; 1997 Apr; 24(4):368-71. PubMed ID: 9096086
[TBL] [Abstract][Full Text] [Related]
23. End-stage renal disease after treatment with 90Y-DOTATOC.
Cybulla M; Weiner SM; Otte A
Eur J Nucl Med; 2001 Oct; 28(10):1552-4. PubMed ID: 11685499
[TBL] [Abstract][Full Text] [Related]
24. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr C; Pless M; Maecke HR; Schumacher T; Crazzolara A; Nitzsche EU; Haldemann A; Mueller-Brand J
J Nucl Med; 2002 May; 43(5):610-6. PubMed ID: 11994522
[TBL] [Abstract][Full Text] [Related]
25. Yttrium-90 DOTATOC: first clinical results.
Otte A; Herrmann R; Heppeler A; Behe M; Jermann E; Powell P; Maecke HR; Muller J
Eur J Nucl Med; 1999 Nov; 26(11):1439-47. PubMed ID: 10552085
[TBL] [Abstract][Full Text] [Related]
26. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study.
Schumacher T; Hofer S; Eichhorn K; Wasner M; Zimmerer S; Freitag P; Probst A; Gratzl O; Reubi JC; Maecke R; Mueller-Brand J; Merlo A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):486-93. PubMed ID: 11914886
[TBL] [Abstract][Full Text] [Related]
27. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
Beukhof CM; Brabander T; van Nederveen FH; van Velthuysen MF; de Rijke YB; Hofland LJ; Franssen GJH; Fröberg LAC; Kam BLR; Visser WE; de Herder WW; Peeters RP
BMC Cancer; 2019 Apr; 19(1):325. PubMed ID: 30953466
[TBL] [Abstract][Full Text] [Related]
28. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
[TBL] [Abstract][Full Text] [Related]
29. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
Bodei L; Cremonesi M; Zoboli S; Grana C; Bartolomei M; Rocca P; Caracciolo M; Mäcke HR; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):207-16. PubMed ID: 12552338
[TBL] [Abstract][Full Text] [Related]
30. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study.
Stokkel MP; Verkooijen RB; Bouwsma H; Smit JW
Nucl Med Commun; 2004 Jul; 25(7):683-90. PubMed ID: 15208495
[TBL] [Abstract][Full Text] [Related]
31. [Somatostatin receptor status in non-medullary thyroid carcinoma].
Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.
Menda Y; O'Dorisio MS; Kao S; Khanna G; Michael S; Connolly M; Babich J; O'Dorisio T; Bushnell D; Madsen M
J Nucl Med; 2010 Oct; 51(10):1524-31. PubMed ID: 20847174
[TBL] [Abstract][Full Text] [Related]
33. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
[TBL] [Abstract][Full Text] [Related]
34. Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity.
Czepczyński R; Matysiak-Grześ M; Gryczyńska M; Bączyk M; Wyszomirska A; Stajgis M; Ruchała M
Arch Immunol Ther Exp (Warsz); 2015 Apr; 63(2):147-54. PubMed ID: 25403743
[TBL] [Abstract][Full Text] [Related]
35. 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas.
Gerster-Gilliéron K; Forrer F; Maecke H; Mueller-Brand J; Merlo A; Cordier D
J Nucl Med; 2015 Nov; 56(11):1748-51. PubMed ID: 26294303
[TBL] [Abstract][Full Text] [Related]
36. [Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
Otte A; Herrmann R; Mäcke HR; Müller-Brand J
Praxis (Bern 1994); 1999 Aug; 88(31-32):1263-8. PubMed ID: 10479965
[TBL] [Abstract][Full Text] [Related]
37. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies.
Paganelli G; Bodei L; Handkiewicz Junak D; Rocca P; Papi S; Lopera Sierra M; Gatti M; Chinol M; Bartolomei M; Fiorenza M; Grana C
Biopolymers; 2002; 66(6):393-8. PubMed ID: 12658726
[TBL] [Abstract][Full Text] [Related]
38. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bernard BF; De Bruin E; Van Gameren A; Bakker WH; Visser TJ; Mäcke HR; Krenning EP
Nucl Med Commun; 1998 Mar; 19(3):283-8. PubMed ID: 9625504
[TBL] [Abstract][Full Text] [Related]
39. Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide.
Savelli G; Bertagna F; Franco F; Dognini L; Bosio G; Migliorati E; Rodella C; Biasiotto G; Bettinsoli G; Minari C; Zaniboni A; Ferrari C; Tomassetti P; Ferrari V; Giubbini R
Cancer; 2012 Jun; 118(11):2915-24. PubMed ID: 22020784
[TBL] [Abstract][Full Text] [Related]
40. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.
Rodrigues M; Traub-Weidinger T; Leimer M; Li S; Andreae F; Angelberger P; Dudczak R; Virgolini I
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1144-51. PubMed ID: 15909194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
